Oxford Immunotec to Hold a Virtual Investor Event on December 17, 2020
November 23 2020 - 7:30AM
Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a
global, high-growth diagnostics company, today announced that it
plans to hold a virtual investor event on Thursday, December 17,
2020. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt
McLaughlin, Chief Financial Officer, will host a conference call
from 10:00 a.m. to 12:00 p.m. Eastern Time. The call will be
concurrently webcast with a slide presentation.
The call topics will include:
- A deep dive into the TB market and how investments made over
the past few years have re-positioned the Company to capitalise on
what the Company believes is a great long-term growth opportunity.
This will include an update on the Company’s automation plans and
the role the Company believes automation will play in driving that
growth.
- The longer term vision for the Company including the role of
both organic and inorganic initiatives and deployment plans for the
Company’s balance sheet.
- A briefing on the Company’s SARS-CoV-2 plans. The Company will
provide its views, based on the significant base of evidence
already gathered, on the role that T cells play in SARS-CoV-2, how
they might be used and what the Company’s specific plans are going
forwards for its tests.
To listen to the conference call on your telephone, please dial
(855) 363-5047 for United States callers or +1 (484) 365-2897 for
international callers and reference confirmation code 8665756,
approximately 15 minutes prior to start time. To access the live
audio webcast or subsequent archived recording, visit the Investor
Relations section of Oxford Immunotec's website at
www.oxfordimmunotec.com. The replay will be available on the
Company's website for approximately 60 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics
company. We bring energy and invention to a world in need of
diagnostic truth. We are uniquely placed as the only company in the
world offering regulated ELISPOT assays for T cell measurement,
with approval around the globe. Our leading product, the T-SPOT®.TB
test, is used for diagnosing infection with Tuberculosis, the
world’s largest cause of death from infectious disease. The Company
is an experienced manufacturer of IVD tests, operating under a
fully audited Quality Management System, ensuring rigorous batch
control. The company has manufactured in excess of 20 million
clinical T cell tests for TB infection. The T-SPOT.TB test has been
approved for sale in over 50 countries, including the United
States, where it has received pre-market approval from the Food and
Drug Administration, Europe, where it has obtained a CE mark, as
well as Japan and China. The Company is headquartered near Oxford,
U.K. and in Marlborough, MA. Additional information can be found at
www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford
Immunotec Ltd.
CONTACTS:
For Media and Investor Inquiries: Matt
McLaughlinChief Financial OfficerOxford ImmunotecTel: +1 (508)
573-9953mtmclaughlin@oxfordimmunotec.com
Oxford Immunotec Global (NASDAQ:OXFD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Immunotec Global (NASDAQ:OXFD)
Historical Stock Chart
From Apr 2023 to Apr 2024